$27,106.67 speaking Payment -- Bristol-Myers Squibb to Dr. James Wilson
Bristol-Myers Squibb pays Rheumatologist James Wilson over $27,000 for speaking on Revlimid
This page provides a detailed analysis of a $27,106.67 speaking payment from Bristol-Myers Squibb to Dr. James Wilson. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $27,106.67 |
| Payment Type | speaking |
| Payment Nature | Compensation for serving as faculty or as a speaker |
| Pharmaceutical Company | Bristol-Myers Squibb |
| Physician | Dr. James Wilson |
| NPI Number | 1175181768 |
| Physician Specialty | Rheumatology |
| Location | Atlanta, GA |
| Date of Payment | 2025-01-24 |
| Related Drug/Device | Revlimid |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Bristol-Myers Squibb made a $27.1K speaking payment to James Wilson, a Rheumatology specialist in Atlanta, GA. The payment was associated with Revlimid. The payment of $27,106.67 to Dr. James Wilson from Bristol-Myers Squibb for speaking engagements related to Revlimid is a significant amount. This payment falls under 'Compensation for serving as faculty or as a speaker,' indicating an educational or promotional role. The payment was made on January 24, 2025, suggesting a recent or future engagement.
Patient Guidance: What This Payment Means for You
If your doctor receives payments for speaking, it may be related to educating other healthcare professionals about specific medications or treatments. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for speaking engagements can vary widely, but $27,106.67 is on the higher end for a rheumatologist, potentially indicating a significant role as a key opinion leader or extensive speaking activities.
Regulatory Context: Sunshine Act Requirements
Physicians receiving payments from pharmaceutical companies for speaking must disclose these transactions under the Sunshine Act to ensure transparency in healthcare.
Related Topics
This payment is related to the following healthcare transparency topics:
- speaking-fees
- speaker-program
- pharmaceutical-payments
- drug-promotion
- revlimid
- bristol-myers-squibb
- rheumatology
Understanding speaking Payments
Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.
Frequently Asked Questions About This Payment
What was this $27.1K payment for?
This was a speaking payment of $27.1K from Bristol-Myers Squibb to James Wilson, categorized as "Compensation for serving as faculty or as a speaker". It was associated with Revlimid. The payment was reported under the Sunshine Act (CMS Open Payments).
Does James Wilson accept pharmaceutical money?
Yes, James Wilson received this $27.1K payment from Bristol-Myers Squibb. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view James Wilson's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this speaking payment?
A speaking payment of $27.1K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Rheumatology?
To compare this payment against Rheumatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Rheumatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about James Wilson's relationship with Bristol-Myers Squibb?
The payment amount is substantial for a single speaking engagement or series of engagements. This $27.1K speaking payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Rheumatology?
The specific drug, Revlimid, is a key focus of the payment's nature.
What should patients do after learning about this payment?
If your doctor receives payments for speaking, it may be related to educating other healthcare professionals about specific medications or treatments.
What else should I know about this speaking payment?
Dr. Wilson's specialty is Rheumatology, aligning with the potential use of Revlimid.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.